Lyell Immunopharma (LYEL) Competitors

$16.13 -0.38 (-2.30%)

Closing price 04:00 PM Eastern

Extended Trading

$16.16 +0.04 (+0.22%)

As of 04:10 PM Eastern

LYEL vs. ANIP, ZYME, PVLA, HRMY, and QURE

Should you buy Lyell Immunopharma stock or one of its competitors? MarketBeat compares Lyell Immunopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lyell Immunopharma include ANI Pharmaceuticals (ANIP), Zymeworks (ZYME), Palvella Therapeutics (PVLA), Harmony Biosciences (HRMY), and uniQure (QURE). These companies are all part of the "pharmaceutical products" industry.

How does Lyell Immunopharma compare to ANI Pharmaceuticals?

ANI Pharmaceuticals (NASDAQ:ANIP) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

ANI Pharmaceuticals currently has a consensus price target of $107.33, suggesting a potential upside of 33.63%. Lyell Immunopharma has a consensus price target of $43.00, suggesting a potential upside of 166.58%. Given Lyell Immunopharma's higher probable upside, analysts clearly believe Lyell Immunopharma is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.63
Lyell Immunopharma	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

ANI Pharmaceuticals has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market.

76.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by company insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ANI Pharmaceuticals has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	2.07	$78.34M	$3.95	20.33
Lyell Immunopharma	$40K	9,407.82	-$274.45M	-$13.80	N/A

ANI Pharmaceuticals has a net margin of 9.98% compared to Lyell Immunopharma's net margin of -794,858.12%. ANI Pharmaceuticals' return on equity of 27.51% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	9.98%	27.51%	10.02%
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%

In the previous week, ANI Pharmaceuticals had 10 more articles in the media than Lyell Immunopharma. MarketBeat recorded 16 mentions for ANI Pharmaceuticals and 6 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 0.93 beat ANI Pharmaceuticals' score of -0.27 indicating that Lyell Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lyell Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ANI Pharmaceuticals beats Lyell Immunopharma on 13 of the 17 factors compared between the two stocks.

How does Lyell Immunopharma compare to Zymeworks?

Lyell Immunopharma (NASDAQ:LYEL) and Zymeworks (NASDAQ:ZYME) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

In the previous week, Zymeworks had 7 more articles in the media than Lyell Immunopharma. MarketBeat recorded 13 mentions for Zymeworks and 6 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 0.93 beat Zymeworks' score of 0.57 indicating that Lyell Immunopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lyell Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zymeworks	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zymeworks has higher revenue and earnings than Lyell Immunopharma. Zymeworks is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40K	9,407.82	-$274.45M	-$13.80	N/A
Zymeworks	$105.96M	16.81	-$81.13M	-$1.37	N/A

Zymeworks has a net margin of -126.92% compared to Lyell Immunopharma's net margin of -794,858.12%. Zymeworks' return on equity of -37.97% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%
Zymeworks	-126.92%	-37.97%	-25.31%

Lyell Immunopharma has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market. Comparatively, Zymeworks has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Lyell Immunopharma currently has a consensus target price of $43.00, indicating a potential upside of 166.58%. Zymeworks has a consensus target price of $38.00, indicating a potential upside of 55.74%. Given Lyell Immunopharma's higher probable upside, research analysts clearly believe Lyell Immunopharma is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92

66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by company insiders. Comparatively, 33.5% of Zymeworks shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Zymeworks beats Lyell Immunopharma on 13 of the 17 factors compared between the two stocks.

How does Lyell Immunopharma compare to Palvella Therapeutics?

Lyell Immunopharma (NASDAQ:LYEL) and Palvella Therapeutics (NASDAQ:PVLA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

Palvella Therapeutics has higher revenue and earnings than Lyell Immunopharma. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40K	9,407.82	-$274.45M	-$13.80	N/A
Palvella Therapeutics	$42.81M	36.58	-$41.72M	-$4.17	N/A

66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by insiders. Comparatively, 20.5% of Palvella Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Palvella Therapeutics had 1 more articles in the media than Lyell Immunopharma. MarketBeat recorded 7 mentions for Palvella Therapeutics and 6 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 0.93 beat Palvella Therapeutics' score of -0.43 indicating that Lyell Immunopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lyell Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palvella Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Palvella Therapeutics has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -794,858.12%. Palvella Therapeutics' return on equity of -56.87% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%
Palvella Therapeutics	N/A	-56.87%	-42.50%

Lyell Immunopharma presently has a consensus target price of $43.00, indicating a potential upside of 166.58%. Palvella Therapeutics has a consensus target price of $199.53, indicating a potential upside of 82.72%. Given Lyell Immunopharma's higher possible upside, research analysts clearly believe Lyell Immunopharma is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

Lyell Immunopharma has a beta of -0.05, indicating that its stock price is 105% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.13, indicating that its stock price is 113% less volatile than the broader market.

Summary

Palvella Therapeutics beats Lyell Immunopharma on 10 of the 16 factors compared between the two stocks.

How does Lyell Immunopharma compare to Harmony Biosciences?

Lyell Immunopharma (NASDAQ:LYEL) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Lyell Immunopharma has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

In the previous week, Lyell Immunopharma had 2 more articles in the media than Harmony Biosciences. MarketBeat recorded 6 mentions for Lyell Immunopharma and 4 mentions for Harmony Biosciences. Lyell Immunopharma's average media sentiment score of 0.93 beat Harmony Biosciences' score of 0.74 indicating that Lyell Immunopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lyell Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harmony Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harmony Biosciences has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40K	9,407.82	-$274.45M	-$13.80	N/A
Harmony Biosciences	$868.45M	2.03	$158.69M	$2.48	12.27

Lyell Immunopharma presently has a consensus target price of $43.00, indicating a potential upside of 166.58%. Harmony Biosciences has a consensus target price of $40.89, indicating a potential upside of 34.33%. Given Lyell Immunopharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Lyell Immunopharma is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
Harmony Biosciences	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

Harmony Biosciences has a net margin of 16.20% compared to Lyell Immunopharma's net margin of -794,858.12%. Harmony Biosciences' return on equity of 17.19% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%
Harmony Biosciences	16.20%	17.19%	11.99%

66.1% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 6.2% of Lyell Immunopharma shares are owned by insiders. Comparatively, 11.0% of Harmony Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Harmony Biosciences beats Lyell Immunopharma on 11 of the 17 factors compared between the two stocks.

How does Lyell Immunopharma compare to uniQure?

uniQure (NASDAQ:QURE) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

uniQure has a net margin of -1,154.42% compared to Lyell Immunopharma's net margin of -794,858.12%. Lyell Immunopharma's return on equity of -85.71% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,154.42%	-145.81%	-27.15%
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%

uniQure currently has a consensus target price of $42.83, indicating a potential upside of 73.48%. Lyell Immunopharma has a consensus target price of $43.00, indicating a potential upside of 166.58%. Given Lyell Immunopharma's higher possible upside, analysts plainly believe Lyell Immunopharma is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53
Lyell Immunopharma	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

uniQure has higher revenue and earnings than Lyell Immunopharma. uniQure is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	96.72	-$198.97M	-$3.48	N/A
Lyell Immunopharma	$40K	9,407.82	-$274.45M	-$13.80	N/A

In the previous week, Lyell Immunopharma had 3 more articles in the media than uniQure. MarketBeat recorded 6 mentions for Lyell Immunopharma and 3 mentions for uniQure. Lyell Immunopharma's average media sentiment score of 0.93 beat uniQure's score of 0.90 indicating that Lyell Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lyell Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.8% of uniQure shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 4.8% of uniQure shares are held by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

uniQure has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market.

Summary

uniQure beats Lyell Immunopharma on 9 of the 17 factors compared between the two stocks.

Get Lyell Immunopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LYEL vs. The Competition

Export

Metric	Lyell Immunopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$385.25M	$2.99B	$6.25B	$12.23B
Dividend Yield	N/A	1.96%	2.80%	5.32%
P/E Ratio	-1.17	17.04	20.79	25.05
Price / Sales	9,407.82	251.21	531.21	72.69
Price / Cash	N/A	57.15	43.09	54.25
Price / Book	1.38	4.39	9.81	6.83
Net Income	-$274.45M	$74.99M	$3.55B	$335.69M
7 Day Performance	-16.21%	-4.89%	-2.07%	-2.03%
1 Month Performance	-32.82%	-8.30%	-3.90%	-1.90%
1 Year Performance	95.23%	28.66%	29.39%	27.36%

Lyell Immunopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LYEL Lyell Immunopharma	2.3719 of 5 stars	$16.13 -2.3%	$43.00 +166.6%	+98.9%	$385.25M	$40K	N/A	270	News Coverage Analyst Revision Gap Down
ANIP ANI Pharmaceuticals	3.2218 of 5 stars	$79.50 +1.0%	$107.33 +35.0%	+32.3%	$1.76B	$883.37M	20.13	600
ZYME Zymeworks	3.2448 of 5 stars	$23.90 -0.5%	$38.00 +59.0%	N/A	$1.75B	$105.96M	N/A	460	Buyback Announcement
PVLA Palvella Therapeutics	3.1021 of 5 stars	$125.79 +3.0%	$199.53 +58.6%	+376.4%	$1.75B	$42.81M	N/A	N/A
HRMY Harmony Biosciences	4.7439 of 5 stars	$30.15 -0.1%	$40.89 +35.6%	-14.9%	$1.75B	$868.45M	12.16	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LYEL) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lyell Immunopharma (LYEL) Competitors

LYEL vs. ANIP, ZYME, PVLA, HRMY, and QURE

How does Lyell Immunopharma compare to ANI Pharmaceuticals?

Summary

How does Lyell Immunopharma compare to Zymeworks?

Summary

How does Lyell Immunopharma compare to Palvella Therapeutics?

Summary

How does Lyell Immunopharma compare to Harmony Biosciences?

Summary

How does Lyell Immunopharma compare to uniQure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL vs. The Competition

Lyell Immunopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lyell Immunopharma (LYEL) Competitors

LYEL vs. ANIP, ZYME, PVLA, HRMY, and QURE

How does Lyell Immunopharma compare to ANI Pharmaceuticals?

Do analysts rate ANIP or LYEL?

Which has more volatility and risk, ANIP or LYEL?

Do insiders & institutionals hold more shares of ANIP or LYEL?

Which has better valuation and earnings, ANIP or LYEL?

Is ANIP or LYEL more profitable?

Does the media favor ANIP or LYEL?

Summary

How does Lyell Immunopharma compare to Zymeworks?

Does the media prefer LYEL or ZYME?

Which has stronger valuation and earnings, LYEL or ZYME?

Is LYEL or ZYME more profitable?

Which has more risk & volatility, LYEL or ZYME?

Do analysts rate LYEL or ZYME?

Do insiders & institutionals believe in LYEL or ZYME?

Summary

How does Lyell Immunopharma compare to Palvella Therapeutics?

Which has stronger valuation & earnings, LYEL or PVLA?

Do insiders and institutionals have more ownership in LYEL or PVLA?

Does the media refer more to LYEL or PVLA?

Is LYEL or PVLA more profitable?

Do analysts rate LYEL or PVLA?

Which has more volatility & risk, LYEL or PVLA?

Summary

How does Lyell Immunopharma compare to Harmony Biosciences?

Which has more volatility & risk, LYEL or HRMY?

Does the media favor LYEL or HRMY?

Which has better earnings and valuation, LYEL or HRMY?

Do analysts rate LYEL or HRMY?

Is LYEL or HRMY more profitable?

Do institutionals and insiders believe in LYEL or HRMY?

Summary

How does Lyell Immunopharma compare to uniQure?

Is QURE or LYEL more profitable?

Do analysts prefer QURE or LYEL?

Which has higher earnings & valuation, QURE or LYEL?

Does the media refer more to QURE or LYEL?

Do insiders and institutionals believe in QURE or LYEL?

Which has more volatility and risk, QURE or LYEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL vs. The Competition

Lyell Immunopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools